Mangalam Drugs & Organics Limited (NSE:MANGALAM)
India · Delayed Price · Currency is INR 30.50
+0.95 (3.21%)
Apr 6, 2026, 3:28 PM IST
Mangalam Drugs & Organics Revenue
Mangalam Drugs & Organics had revenue of 583.76M INR in the quarter ending December 31, 2025, a decrease of -34.08%. This brings the company's revenue in the last twelve months to 2.38B, down -31.47% year-over-year. In the fiscal year ending March 31, 2025, Mangalam Drugs & Organics had annual revenue of 3.18B, down -13.55%.
Revenue (ttm)
2.38B
Revenue Growth
-31.47%
P/S Ratio
0.19
Revenue / Employee
4.95M
Employees
480
Market Cap
461.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | 3.80B | 976.24M | 34.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Sigachi Industries | 4.85B |
| Sakar Healthcare | 2.31B |
| Valiant Laboratories | 2.03B |
| Bafna Pharmaceuticals | 1.47B |
| Alpa Laboratories | 1.14B |
| Vaishali Pharma | 1.14B |
| Par Drugs and Chemicals | 1.06B |